

Appl. No. : 10/719,532  
Filed : November 21, 2003

RECEIVED  
CENTRAL FAX CENTER  
SEP 19 2006

**REMARKS**

In response to the Restriction Requirement mailed August 8, 2006, Applicant elects Group I, which corresponds to Claims 3-6 and 8. Claims 1-24 are pending, and Applicant respectfully requests that the Examiner examine the pending claims on the merits.

Applicant has submitted an Information Disclosure Statement herewith, which includes the International Preliminary Examination Report for PCT Application No. PCT/US02/16517. The present application is a continuation of the PCT application. Applicant respectfully directs the Examiner's attention to page 4, where the PCT Examiner determined that Claim 6 possessed novelty, invention step, and industrial applicability because:

**[T]he prior art does not teach or fairly suggest the helminthic antigen is an isolated protein selected from the group consisting of *Capillaria hepatica* and *Dicrocoelium dendriticum*.**

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 19, 2006

By: 

Salima A. Merani, J.D., Ph.D.  
Registration No. L0236  
Attorney at Law  
Customer No. 20,995  
(949) 760-0404

2928181  
091906